Table 3.
Areas with Significant Changes in BOLD Signal for the contrast incongruent greater than congruent following smoking cessation therapy with varenicline.
| Region | Hem | x, y, z | Cluster size | peak t-Value |
|---|---|---|---|---|
| BASELINE>WEEK 12 | ||||
| Anterior cingulum | L | −5, 48, 0 | 840 | 7.76 |
| Cluster sub regions | ||||
| Anterior cingulum | R | 404 | ||
| Middle cingulum | R | 229 | ||
| Precuneus | R | 430 | ||
| Caudate | L | 203 | ||
| Superior frontal | R | 159 | ||
| Medial sup frontal | L, R | 819, 279 | ||
| Medial OFC | L, R | 324, 152 | ||
| Middle temporal | L | −50, −41, 12 | 339 | 6.51 |
Hem, hemisphere; OFC, Orbitofrontal Cortex; SMA, Supplementary Motor Area; x, y, z refers to Montreal Neurological Institute coordinates. All regions are significant at a cluster level threshold of p < 0.05 FWE cluster level corrected. No regions survived thresholding in Week 12 > Baseline contrast. See Table S1 for within group results.